A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

NCT02944448 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

761

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Hip
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

Interventions

DRUG: CR845 tablet 1 mg
DRUG: CR845 tablet 2.5 mg
DRUG: CR845 tablet 5 mg
DRUG: Placebo tablet

Sponsor

Cara Therapeutics, Inc.